Physician profile
John Robert Randolph
NPI 1689677882
$4,893.18
in general payments reported to CMS, 2019-2025
32 companies · $840 in 2025
The $840 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $421 · 2021: $871 · 2022: $747 · 2023: $563 · 2024: $758 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,161.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $870.05 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $775.09 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $540.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $476.70 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.25 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $267.26 | 2020-2025 | Xifaxan |
| Abbvie INC. | $181.35 | 2021-2025 | |
| Amgen INC. | $173.78 | 2019-2021 | |
| Dexcom, INC. | $154.87 | 2021-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $151.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $146.13 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $143.31 | 2019-2023 | |
| Abbott Laboratories | $135.41 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $92.37 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $58.99 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $48.95 | 2019-2021 | |
| Insmed, INC. | $47.69 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $44.62 | 2019-2022 | |
| Esperion Therapeutics, INC. | $31.98 | 2020-2021 | |
| Shield Therapeutics INC | $30.41 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $29.81 | 2019-2022 | |
| Allergan, INC. | $29.64 | 2019 | |
| Phathom Pharmaceuticals, INC. | $28.78 | 2025 | Voquezna |
| Medtronic, INC. | $24.01 | 2025 | Intellis Adaptivestim |
| Astellas Pharma US INC | $22.11 | 2024 | Veozah |
| Ironshore Pharmaceuticals INC. | $21.16 | 2019 | |
| Cranial Technologies, INC | $17.54 | 2024 | Doc Band |
| Daiichi Sankyo INC. | $16.21 | 2021 | |
| Shire North American Group INC | $14.84 | 2019 | |
| Eisai INC. | $14.68 | 2021 | |
| Adlon Therapeutics L.P. | $13.08 | 2020 | |
| Supernus Pharmaceuticals, INC. | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Randolph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.